Share Talk took the opportunity to speak with N4 Pharma's Founder and CEO Nigel Theobald following their admission and first day of shares being available for dealing on AIM.

Nigel touched on the progress made by N4P since he founded the company in 2014 and the goals and ambitions he and his very experienced team now have for the listed company. Especially with its patents, intellectual property (IP) and portfolio of products and opportunities.

Nigel explains N4P's low risk business model and their strategy for getting products commercial ready and growing their pipeline and IP.

Nigel gave an overview of N4P's generic and vaccine products and opportunities.

He added that N4 Pharma are seeking to improve the speed at which Sildenafil (commonly known as Viagra) takes effect whilst also extending its duration of action. It is envisaged by Nigel and his his team that they could have Sildenafil commercial ready in 2018.

Listen now to CEO Nigel Theobald on what N4 Pharma has to offer.

#N4P #ONZ